Therapeutic efficacy of fluoropyrimidines depends on the duration of thymidylate synthase inhibition in the murine colon 26-B carcinoma tumor model

Clinical Cancer Research

Volumn 2, Issue 8, 1996, Pages 1327-1333

  Van Laar, Jan A M ^a,b   Van Der Wilt, Clasina L ^a   Rustum, Youcef M ^b   Noordhuis, Paul ^a   Smid, Kees ^a   Pinedo, Herbert M ^a   Peters, Godefridus J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROPYRIMIDINE; FLUOROURACIL; THYMIDYLATE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GROWTH INHIBITION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PYRIMIDINE SYNTHESIS;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; COLONIC NEOPLASMS; FEMALE; FLOXURIDINE; FLUORODEOXYURIDYLATE; FLUOROURACIL; MICE; MICE, INBRED BALB C; RNA; THYMIDYLATE SYNTHASE; TIME FACTORS;

EID: 0029760529     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Kemeny, N., Lokich, J. J., Anderson, N., and Ahlgren, J. D. Recent advances in the treatment of advanced colorectal cancer. Cancer (Phila.), 71: 9-18, 1993.
2. Pinedo, H. M., and Peters, G. J. 5-Fluorouracil: biochemistry and pharmacology J. Clin. Oncol., 6: 1653-1664, 1988.
3. Danenberg, P. V. Thymidylate synthetase - a target enzyme in cancer chemotherapy. Biochim. Biophys. Acta, 473. 73-92, 1977.
4. Spears, C. P., Shahinian, A. H., Moran, R. C., Heidelberger, C , and Corbett, T. H. In vivo kinetics of thymidylate synthetase inhibition in FUra-sensitive and -resistant murine colon adenocarcinomas. Cancer Res., 42: 450-456, 1982
5. Zhang, Z. G., Harstrick, A., and Rustum, Y. M. Modulation of fluoropyrimidines: role of dose and schedule of leucovorin administration. Semin. Oncol., 19 (Suppl. 3): 10-15, 1992.
6. Rustum, Y. M. Modulation of fluoropyrimidines by leucovorin: rational and status. J. Surg. Oncol., 2: (Suppl.): 116-123, 1991.
7. Santi, D. V., McHenry. C. S., and Sommer, H. Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridine Biochemistry, 13: 471-481, 1974.
8. Van der Wilt, C. L., Pinedo, H. M., Smid, K., and Peters, G. J. Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by the addition of leucovorin in murine colon tumors. Cancer Res., 52: 4922-4928, 1992.
9. Peters, G. J., Van der Wilt, C. L., Van Groeningen, C. L, Smid, K., Meijer, S., and Pinedo, H. M. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J. Clin. Oncol., 12: 2035-2042, 1994.
10. Swain, S. M., Lippmann. M. E., Egan, E. F., Steinberg, S. M., and Allegra, C. J. Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J. Clin. Oncol., 7: 890-899, 1989.
11. Woodman, P. W., Sarrif, A. M., and Heidelberger, C. Specificity of pyrimidine nucleoside phosphorylases and the phosphorylasis of 5-fluoro-2′-deoxyuridine. Cancer Res., 40: 507-511, 1980.
12. Uchida, M., Ho, D. H. W., Kamiya, K., Yoshimura, T., Sasaki. K., Tsutani, H , and Nakamura. T. Transport and intracellular metabolism of fluorinated pyrimidines in cultured cell lines. In: K. Mikanagi, K. Nishioka, and W. N. Kelley. (eds.), Purine and Pyrimidine Metabolism in Man, Vol. VIB, pp. 321-326. New York: Plenum Publishing Corp., 1989.
13. Uchida, M., Brown, N., and Ho, D. H. W. Enzymatic conversion of 5-fluoro-2′-deoxyuridine to 5-fluorouracil or 5-fluoro-2′-monophosphate in human tissues. Anticancer Res., 10: 779-784, 1990.
14. Creaven, P. J., Rustum, Y. M., Petrelli, N. J., Meropol, N. J., Raghavan, D., Rodriguez-Bigas, M., Levine, E. G., Frank, C., UdvaryNagy, S., and Proefrock, A. T. I. Phase I and pharmacokinetic evaluation of floxuridine/leucovorin given on the Roswell Park weekly regimen. Cancer Chemother. Pharmacol., 34: 261-265, 1994.
15. Spiegelman, S., Sawyer, R. C., Nayak, R., Ritzi, E., Stolfi, R. L., and Martin, D. S. Improving the antitumor activity of 5-fluorouracil by increasing its incorporation into RNA via metabolic modulation. Proc. Natl. Acad. Sci. USA, 77: 4966-4970, 1980.
16. Lönn, U., and Lönn, S. DNA lesions in human neoplasmatic cells and cytotoxicity of 5-fluoropyrimidines. Cancer Res., 46: 3866-3871, 1986.
17. Aschele, C., Sobrero, A., Faderan, M. A., and Bertino, J. R. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res., 52: 1855-1864, 1992.
18. Yin, M. B., and Rustum, Y. M. Comparative DNA strand breakage induced by FUra and FdUrd in human ileocecal adenocarcinoma (HCT-8) cells: relevance to cell growth inhibition. Cancer Commun., 3: 45-51, 1991.
19. Johnston, P. G., Lenz, H-J., Leichman. C. G., Danenberg, K. D., Allegra, C. J., Danenberg, P. V., and Leichman, L. Thymidylate synthase gene protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res., 55: 1407-1412, 1995.
20. Nord L. D., and Martin D. S. Loss of murine tumor thymidine kinase activity in vivo following 5-fluorouracil (FUra) treatment by incorporation of FUra into RNA. Biochem. Pharmacol., 42: 2369-2375, 1991.
21. Van der Wilt, C. L, and Peters G. J. New targets for pyrimidine antimetabolites for the treatment of solid tumors: I. Thymidylate synthase. Pharmacy World & Sci., 16: 84-103, 1994.
22. Cao, S., Zhang, Z., Crcavcn, P. J., and Rustum, Y. M. 5-Fluoro-2′-deoxyuridine: role of schedule in its therapeutic efficacy, In: Y. M. Rustum (ed.), Novel Approaches to Selective Treatment of Human Solid Tumors: Laboratory and Clinical Correlation, pp. 1-8. New York: Plenum Publishing Corp., New York, 1993.
23. Sullivan, R. D., Young, C. W., Miller, E., Glatstein, N., Clarkson, B., and Burchenal J. H. The clinical effects of the continuous administration of fluorinated pyrimidines (5-fluorouracil and 5-fluoro-2′-deoxyuridine). Cancer Chemother Rep., 8: 77-83, 1960.
24. Moertel, C. G., Reitemeier, R. J., and Hahn, R. G. A controlled comparison of 5-fluoro-2′-deoxyundine therapy administered by rapid intravenous injection and by continuous intravenous infusion. Cancer Res., 27: 545-552, 1977.
25. De Takats P. G., Kerr, D. J., Poole, C. J., Warren H. W., and McArdle C. S. Hepatic arterial chemotherapy for metastatic colorectal carcinoma. Br. J. Cancer, 69: 372-378, 1994.
26. Von Roemeling, R., and Hrushesky, W. J. M. Circadian patterning of continuous floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer. J. Clin. Oncol., 11: 1710-1719, 1989.
27. Leichman, C. G. Prolonged infusion of fluorinated pyrimidines in gastrointestinal malignancies: a review of recent clinical trials. Cancer Invest., 12: 166-175. 1994.
28. van Laar, J. A. M., Durrani, F. A., and Rustum, Y. M. Antitumor activity of the weekly push schedule of 5-fluoro-2′-deoxyundine ± N-phosphonacetyl-L-aspartate in mice bearing advanced colon carcinoma 26. Cancer Res.. 53: 1560-1564, 1993.
29. Corbett, T. H., Griswold, D. P., Roberts, B. J., Peckham, J. C., and Schabel, F. M. Tumor induction relationship in development of transplantable cancer of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res., 35: 2434-2439, 1975.
30. Bradford, M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem., 72: 248-254, 1976.
31. Peters, G. J., Lankelma, J., Kok, R. M., Noordhuis, P., Van Groeningen, C. J., Van der Wilt, C. L., Meyer, S., and Pinedo, H. M. Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma. Cancer Chemother. Pharmacol., 31: 269-276, 1993.
32. Peters, G. J., Noordhuis, P., Komissarov. A., Holwerda, U., Kok, R. M., Van Laar, J. A. M., Van der Wilt, C. L., Van Groeningen, C. J., and Pinedo, H. M. Quantification of 5-fluorouracil incorporation into RNA of human and murine tumors as measured with a sensitive gaschromatography-mass spectrometry assay. Anal. Biochem., 231: 157-163, 1995.
33. 19F nuclear magnetic resonance spectroscopy. Cancer Res., 54: 4321-4326, 1994.
34. Codacci-Pisanelli, G., Van der Wilt, C. L., Pinedo, H. M., Franchi, F., Noordhuis, P., Braakhuis. B. J. M., Van Laar. J. A. M., and Peters, G. J. Antitumour activity, toxicity and inhibition of thymidylate synthetase of prolonged administration of 5-fluorouracil in mice. Eur. J. Cancer, 32A: 1517-1525, 1995.
35. Peters, G. J., Braakhuis, B. J. M., De Bruijn, E. A., Laurensse, E. J., Van Walsum, M., and Pinedo, H. M. Enhanced therapeutic efficacy of 5′deoxy-5-fluorouridine in 5-fluorouracil resistant head and neck tumours in relation to 5-fluorouracil metabolising enzymes. Br. J. Cancer, 59: 327-334, 1989.
36. El Kouni, M. H., El Kouni, M. M., and Naguib, F. N. Differences in activities and substrate specificity of human and murine pyrimidine nucleoside phosphorylases: implications for chemotherapy with 5-fluoropyrimidines. Cancer Res., 53: 3687-3693, 1993.
37. Peters, G. J., Van Groeningen, C. J., Laurensse, E. J., and Pinedo, H. M. A comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa. Cancer (Phila.), 68: 1903-1909, 1991.
38. 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits. Proc. Natl. Acad. Sci. USA, 87: 492-496, 1990
39. Bagrij, T., Kralovansky, J., Gyergyay, F., Kiss, E., and Peters, G. J. Influence of uridine treatment in mice on the protection of gastrointestinal toxicity caused by 5-fluorouracil. Anticancer Res , 13: 789-794, 1993.
40. Van Groeningen, C. J., Peters, G. J., Leyva, A., Laurensse, E., and Pinedo, H. M. Reversal of 5-fluorouracil-induced myelosuppression by prolonged administration of high-dose uridine. J. Natl. Cancer Inst., 81: 157-162, 1989.
41. 1 murine mammary carcinoma system. Pharm. Res. (NY), 2: 69-75, 1984.
42. Peters, G. J., Van Dijk, J., Laurensse, E., Van Groeningen, C. J., Lankelma, J., Leyva, A., Nadal, J. C., and Pinedo, H. M. In vitro biochemical and in vivo biological studies of uridine "rescue" of 5-fluorouracil. Br. J. Cancer. 57: 259-265, 1988.
43. Houghton, J. A., Houghton, P. J., and Wooten, R. S. Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluoroundine, and 5-fluoro-2′-deoxyuridine. Cancer Res., 39: 2406-2413, 1979
44. Zhang, Z. G., Harstrick, A., and Rustum Y. M. Mechanisms of resistance to fluoropyrimidines. Semin. Oncol., 19 (Suppl. 3); 4-9, 1992.
45. Jenh, C. H., Geyer, P. K., Baskin, F., and Johnson, L. F. Thymidylate synthase gene amplification in fluorodeoxyuridme-resistant mouse cell lines. Mol. Pharmacol, 28: 80-84, 1985.
46. Freemantle, S. J., Aherne, G. W., Hardcastle, A., Lunec, J., and Calvert, A. H. Increases in thymidylate synthase protein levels measured using newly developed antibodies. Proc. Am. Assoc. Cancer Res., 32: 360, 1991.
47. Chu, E., Koeller, D. M., Johnston, P. G., Zinn, S., and Allegra, C. J. Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-γ. Mol. Pharmacol., 43: 527-533, 1993.
48. Van Laar, J. A. M., Rustum, Y. M., Van der Wilt, C. L., Smid, K., Pinedo, H. M., and Peters, G. J. Tumor size and origin determine antitumor Activity of cis-platin or 5-fluorouracil and its modulation by leucovorin in murine colon carcinomas. Cancer Chemother. Pharmacol., in press, 1996.
49. Jackman, A. M., and Calvert, A. H. Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann. Oncol., 6: 871-881, 1995.
50. Touroutoglou, N., and Pazdur R. Thymidylate synthase inhibitors. Clin. Cancer Res., 2: 227-243. 1996.